ID   UACC-903
AC   CVCL_4052
SY   UACC 903; UACC903; University of Arizona Cell Culture-903
DR   BTO; BTO:0005060
DR   EFO; EFO_0022581
DR   cancercelllines; CVCL_4052
DR   ChEMBL-Cells; CHEMBL3307961
DR   ChEMBL-Targets; CHEMBL612446
DR   Cosmic; 706103
DR   Cosmic; 888843
DR   Cosmic; 897489
DR   Cosmic; 905860
DR   Cosmic; 1020269
DR   Lonza; 39
DR   PubChem_Cell_line; CVCL_4052
DR   Wikidata; Q54973868
RX   PubMed=2068080;
RX   PubMed=2300817;
RX   PubMed=9598804;
RX   PubMed=9692547;
RX   PubMed=9823299;
RX   PubMed=9973934;
RX   PubMed=10766161;
RX   PubMed=10952317;
RX   PubMed=12115485;
RX   PubMed=15009714;
RX   PubMed=19383853;
RX   PubMed=23039341;
RX   PubMed=24879157;
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=9598804).
CC   Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (PubMed=9598804).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Asp (c.1799_1800delTGinsAT); ClinVar=VCV000375939; Zygosity=Unspecified (PubMed=15009714).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Tyr76Ter (c.228T>G); ClinVar=VCV000546013; Zygosity=Unspecified (PubMed=9692547; PubMed=10766161; PubMed=15009714).
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: Metastatic; Back; UBERON=UBERON_0001137.
DI   NCIt; C3510; Cutaneous melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   25Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 10-09-24; Version: 25
//
RX   PubMed=2068080; DOI=10.1073/pnas.88.14.6028; PMCID=PMC52015;
RA   Cornil I., Theodorescu D., Man S., Herlyn M., Jambrosic J.A.,
RA   Kerbel R.S.;
RT   "Fibroblast cell interactions with human melanoma cells affect tumor
RT   cell growth as a function of tumor progression.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:6028-6032(1991).
//
RX   PubMed=2300817; DOI=10.1126/science.2300817;
RA   Trent J.M., Stanbridge E.J., McBride H.L., Meese E.U., Casey G.,
RA   Araujo D.E., Witkowski C.M., Nagle R.B.;
RT   "Tumorigenicity in human melanoma cell lines controlled by
RT   introduction of human chromosome 6.";
RL   Science 247:568-571(1990).
//
RX   PubMed=9598804; DOI=10.1002/(SICI)1098-2264(199806)22:2<157::AID-GCC11>3.0.CO;2-N;
RA   Walker G.J., Flores J.F., Glendening J.M., Lin A.H.-T., Markl I.D.C.,
RA   Fountain J.W.;
RT   "Virtually 100% of melanoma cell lines harbor alterations at the DNA
RT   level within CDKN2A, CDKN2B, or one of their downstream targets.";
RL   Genes Chromosomes Cancer 22:157-163(1998).
//
RX   PubMed=9692547; DOI=10.1038/sj.onc.1201881;
RA   Tsao H., Zhang X., Benoit E., Haluska F.G.;
RT   "Identification of PTEN/MMAC1 alterations in uncultured melanomas and
RT   melanoma cell lines.";
RL   Oncogene 16:3397-3402(1998).
//
RX   PubMed=9823299;
RA   Khan J., Simon R.M., Bittner M., Chen Y.-D., Leighton S.B., Pohida T.,
RA   Smith P.D., Jiang Y., Gooden G.C., Trent J.M., Meltzer P.S.;
RT   "Gene expression profiling of alveolar rhabdomyosarcoma with cDNA
RT   microarrays.";
RL   Cancer Res. 58:5009-5013(1998).
//
RX   PubMed=9973934; DOI=10.1016/S0165-4608(98)00122-8;
RA   Nelson M.A., Ariza M.E., Yang J.-M., Thompson F.H., Taetle R.,
RA   Trent J.M., Wymer J., Massey-Brown K.S., Broome-Powell M., Easton J.,
RA   Lahti J.M., Kidd V.J.;
RT   "Abnormalities in the p34cdc2-related PITSLRE protein kinase gene
RT   complex (CDC2L) on chromosome band 1p36 in melanoma.";
RL   Cancer Genet. Cytogenet. 108:91-99(1999).
//
RX   PubMed=10766161;
RA   Tsao H., Zhang X., Fowlkes K., Haluska F.G.;
RT   "Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous
RT   melanoma cell lines.";
RL   Cancer Res. 60:1800-1804(2000).
//
RX   PubMed=10952317; DOI=10.1038/35020115;
RA   Bittner M., Meltzer P.S., Chen Y.-D., Jiang Y., Seftor E.A.,
RA   Hendrix M.J.C., Radmacher M.D., Simon R.M., Yakhini Z., Ben-Dor A.,
RA   Sampas N., Dougherty E., Wang E., Marincola F.M., Gooden G.C., Lueders J.,
RA   Glatfelter A., Pollock P.M., Carpten J.D., Gillanders E.M., Leja D.,
RA   Dietrich K., Beaudry C., Berens M.E., Alberts D.S., Sondak V.K.,
RA   Hayward N.K., Trent J.M.;
RT   "Molecular classification of cutaneous malignant melanoma by gene
RT   expression profiling.";
RL   Nature 406:536-540(2000).
//
RX   PubMed=12115485; DOI=10.1002/ijc.10422;
RA   Feng Y.-M., Shi J.-Q., Goldstein A.M., Tucker M.A., Nelson M.A.;
RT   "Analysis of mutations and identification of several polymorphisms in
RT   the putative promoter region of the P34CDC2-related CDC2L1 gene
RT   located at 1P36 in melanoma cell lines and melanoma families.";
RL   Int. J. Cancer 99:834-838(2002).
//
RX   PubMed=15009714; DOI=10.1046/j.0022-202X.2004.22243.x; PMCID=PMC2586668;
RA   Tsao H., Goel V., Wu H., Yang G., Haluska F.G.;
RT   "Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1
RT   inactivation in melanoma.";
RL   J. Invest. Dermatol. 122:337-341(2004).
//
RX   PubMed=19383853; DOI=10.1158/1535-7163.MCT-08-1030; PMCID=PMC3128982;
RA   Su D.M., Zhang Q.-Y., Wang X.-X., He P., Zhu Y.-L.J., Zhao J.-X.,
RA   Rennert O.M., Su Y.A.;
RT   "Two types of human malignant melanoma cell lines revealed by
RT   expression patterns of mitochondrial and survival-apoptosis genes:
RT   implications for malignant melanoma therapy.";
RL   Mol. Cancer Ther. 8:1292-1304(2009).
//
RX   PubMed=23039341; DOI=10.1186/1476-4598-11-75; PMCID=PMC3554420;
RA   Byron S.A., Loch D.C., Wellens C.L., Wortmann A., Wu J.-Y., Wang J.,
RA   Nomoto K., Pollock P.M.;
RT   "Sensitivity to the MEK inhibitor E6201 in melanoma cells is
RT   associated with mutant BRAF and wildtype PTEN status.";
RL   Mol. Cancer 11:75.1-75.15(2012).
//
RX   PubMed=24879157; DOI=10.4161/auto.28594; PMCID=PMC4091172;
RA   Goodall M.L., Wang T., Martin K.R., Kortus M.G., Kauffman A.L.,
RA   Trent J.M., Gately S., MacKeigan J.P.;
RT   "Development of potent autophagy inhibitors that sensitize oncogenic
RT   BRAF V600E mutant melanoma tumor cells to vemurafenib.";
RL   Autophagy 10:1120-1136(2014).
//